SrasV1, France, Analysis, bibRecord, 000336

Development in lipid drugs.

Identifieur interne : 000336 ( France/Analysis ); précédent : 000335; suivant : 000337

Development in lipid drugs.

Auteurs : J. Raulin [France]

Source :

Mini reviews in medicinal chemistry [ 1389-5575 ] ; 2005.

RBID : pubmed:15892690

Descripteurs français

KwdFr :
- Acide glycyrrhizique (pharmacologie), Agents antiVIH (pharmacologie), Agents antiVIH (synthèse chimique), Animaux, Cellules dendritiques (), Cellules dendritiques (métabolisme), Complexe majeur d'histocompatibilité, Cytosine (analogues et dérivés), Cytosine (pharmacologie), Humains, Lipides (), Lipides (immunologie), Lipides (pharmacologie), Lymphocytes T (), Lymphocytes T (métabolisme), Mélanome (), Mélanome (immunologie), Orthopoxvirus (), Orthopoxvirus (croissance et développement), Peptides (), Peptides (immunologie), Peptides (pharmacologie), Phosphonates (pharmacologie), Thérapie antirétrovirale hautement active, VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (croissance et développement), Virus de la variole bovine (), Virus de la variole bovine (croissance et développement), Virus du SRAS (), Virus du SRAS (croissance et développement).
MESH :
- analogues et dérivés : Cytosine.
- croissance et développement : Orthopoxvirus, VIH-1 (Virus de l'Immunodéficience Humaine de type 1), Virus de la variole bovine, Virus du SRAS.
- immunologie : Lipides, Mélanome, Peptides.
- métabolisme : Cellules dendritiques, Lymphocytes T.
- pharmacologie : Acide glycyrrhizique, Agents antiVIH, Cytosine, Lipides, Peptides, Phosphonates.
- synthèse chimique : Agents antiVIH.
- Animaux, Cellules dendritiques, Complexe majeur d'histocompatibilité, Humains, Lipides, Lymphocytes T, Mélanome, Orthopoxvirus, Peptides, Thérapie antirétrovirale hautement active, VIH-1 (Virus de l'Immunodéficience Humaine de type 1), Virus de la variole bovine, Virus du SRAS.

English descriptors

KwdEn :
- Animals, Anti-HIV Agents (chemical synthesis), Anti-HIV Agents (pharmacology), Antiretroviral Therapy, Highly Active, Cidofovir, Cowpox virus (drug effects), Cowpox virus (growth & development), Cytosine (analogs & derivatives), Cytosine (pharmacology), Dendritic Cells (drug effects), Dendritic Cells (metabolism), Glycyrrhizic Acid (pharmacology), HIV-1 (drug effects), HIV-1 (growth & development), Humans, Lipids (chemistry), Lipids (immunology), Lipids (pharmacology), Major Histocompatibility Complex, Melanoma (immunology), Melanoma (prevention & control), Organophosphonates (pharmacology), Orthopoxvirus (drug effects), Orthopoxvirus (growth & development), Peptides (chemistry), Peptides (immunology), Peptides (pharmacology), SARS Virus (drug effects), SARS Virus (growth & development), T-Lymphocytes (drug effects), T-Lymphocytes (metabolism).
MESH :
- chemical , analogs & derivatives : Cytosine.
- chemical , chemical synthesis : Anti-HIV Agents.
- chemical , chemistry : Lipids, Peptides.
- chemical , immunology : Lipids, Peptides.
- chemical , pharmacology : Anti-HIV Agents, Cytosine, Glycyrrhizic Acid, Lipids, Organophosphonates, Peptides.
- drug effects : Cowpox virus, Dendritic Cells, HIV-1, Orthopoxvirus, SARS Virus, T-Lymphocytes.
- growth & development : Cowpox virus, HIV-1, Orthopoxvirus, SARS Virus.
- immunology : Melanoma.
- metabolism : Dendritic Cells, T-Lymphocytes.
- prevention & control : Melanoma.
- Animals, Antiretroviral Therapy, Highly Active, Cidofovir, Humans, Major Histocompatibility Complex.

Abstract

Lipopeptide lipid moieties induce dendritic cell (DC) internalization and epitopes are recognized by MHC, the major histocompatibility complex. HIV-1 (human immunodeficiency virus type 1) lipopeptide vaccine candidate elicits immune responses, and sustains HIV control after highly active antiretroviral therapy (HAART). Mp- and Dp-MART (anti-melanoma lipopeptides) induce strong CTL (cytolytic T lymphocyte) response. New BGTC, BGDA, TGKC lipoplexes mediate gene delivery, e.g., into mouse pancreatic tumor nodules. Triterpene glycyrrhizic acid (GL) inhibits SARS-CoV (severe acute respiratory syndrome associated coronavirus) replication. Compared to CDV (cidofovir), CDV ether lipid esters have enhanced activity against vaccinia (VV) and cowpox (CV) viruses in vitro. Oral treatment of VV and CV infected mice with CDV ether lipid esters, as effective as i.p. CDV, may be useful against orthopoxvirus infections in humans.

DOI: 10.2174/1389557053765574
PubMed: 15892690

Affiliations:

Links to Exploration step

pubmed:15892690

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development in lipid drugs.</title>
<author><name sortKey="Raulin, J" sort="Raulin, J" uniqKey="Raulin J" first="J" last="Raulin">J. Raulin</name>
<affiliation wicri:level="3"><nlm:affiliation>Université Denis Diderot (Paris 7), 2 place Jussieu, 75005 Paris, France. jeanine.raulin@wanadoo.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université Denis Diderot (Paris 7), 2 place Jussieu, 75005 Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="RBID">pubmed:15892690</idno>
<idno type="pmid">15892690</idno>
<idno type="doi">10.2174/1389557053765574</idno>
<idno type="wicri:Area/PubMed/Corpus">002741</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002741</idno>
<idno type="wicri:Area/PubMed/Curation">002741</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002741</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002752</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002752</idno>
<idno type="wicri:Area/Ncbi/Merge">000F47</idno>
<idno type="wicri:Area/Ncbi/Curation">000F47</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000F47</idno>
<idno type="wicri:doubleKey">1389-5575:2005:Raulin J:development:in:lipid</idno>
<idno type="wicri:Area/Main/Merge">004B75</idno>
<idno type="wicri:Area/Main/Curation">004868</idno>
<idno type="wicri:Area/Main/Exploration">004868</idno>
<idno type="wicri:Area/France/Extraction">000336</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Development in lipid drugs.</title>
<author><name sortKey="Raulin, J" sort="Raulin, J" uniqKey="Raulin J" first="J" last="Raulin">J. Raulin</name>
<affiliation wicri:level="3"><nlm:affiliation>Université Denis Diderot (Paris 7), 2 place Jussieu, 75005 Paris, France. jeanine.raulin@wanadoo.fr</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université Denis Diderot (Paris 7), 2 place Jussieu, 75005 Paris</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Mini reviews in medicinal chemistry</title>
<idno type="ISSN">1389-5575</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Anti-HIV Agents (chemical synthesis)</term>
<term>Anti-HIV Agents (pharmacology)</term>
<term>Antiretroviral Therapy, Highly Active</term>
<term>Cidofovir</term>
<term>Cowpox virus (drug effects)</term>
<term>Cowpox virus (growth & development)</term>
<term>Cytosine (analogs & derivatives)</term>
<term>Cytosine (pharmacology)</term>
<term>Dendritic Cells (drug effects)</term>
<term>Dendritic Cells (metabolism)</term>
<term>Glycyrrhizic Acid (pharmacology)</term>
<term>HIV-1 (drug effects)</term>
<term>HIV-1 (growth & development)</term>
<term>Humans</term>
<term>Lipids (chemistry)</term>
<term>Lipids (immunology)</term>
<term>Lipids (pharmacology)</term>
<term>Major Histocompatibility Complex</term>
<term>Melanoma (immunology)</term>
<term>Melanoma (prevention & control)</term>
<term>Organophosphonates (pharmacology)</term>
<term>Orthopoxvirus (drug effects)</term>
<term>Orthopoxvirus (growth & development)</term>
<term>Peptides (chemistry)</term>
<term>Peptides (immunology)</term>
<term>Peptides (pharmacology)</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (growth & development)</term>
<term>T-Lymphocytes (drug effects)</term>
<term>T-Lymphocytes (metabolism)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Acide glycyrrhizique (pharmacologie)</term>
<term>Agents antiVIH (pharmacologie)</term>
<term>Agents antiVIH (synthèse chimique)</term>
<term>Animaux</term>
<term>Cellules dendritiques ()</term>
<term>Cellules dendritiques (métabolisme)</term>
<term>Complexe majeur d'histocompatibilité</term>
<term>Cytosine (analogues et dérivés)</term>
<term>Cytosine (pharmacologie)</term>
<term>Humains</term>
<term>Lipides ()</term>
<term>Lipides (immunologie)</term>
<term>Lipides (pharmacologie)</term>
<term>Lymphocytes T ()</term>
<term>Lymphocytes T (métabolisme)</term>
<term>Mélanome ()</term>
<term>Mélanome (immunologie)</term>
<term>Orthopoxvirus ()</term>
<term>Orthopoxvirus (croissance et développement)</term>
<term>Peptides ()</term>
<term>Peptides (immunologie)</term>
<term>Peptides (pharmacologie)</term>
<term>Phosphonates (pharmacologie)</term>
<term>Thérapie antirétrovirale hautement active</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) ()</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (croissance et développement)</term>
<term>Virus de la variole bovine ()</term>
<term>Virus de la variole bovine (croissance et développement)</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (croissance et développement)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Cytosine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Anti-HIV Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Lipids</term>
<term>Peptides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Lipids</term>
<term>Peptides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-HIV Agents</term>
<term>Cytosine</term>
<term>Glycyrrhizic Acid</term>
<term>Lipids</term>
<term>Organophosphonates</term>
<term>Peptides</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Cytosine</term>
</keywords>
<keywords scheme="MESH" qualifier="croissance et développement" xml:lang="fr"><term>Orthopoxvirus</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term>
<term>Virus de la variole bovine</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cowpox virus</term>
<term>Dendritic Cells</term>
<term>HIV-1</term>
<term>Orthopoxvirus</term>
<term>SARS Virus</term>
<term>T-Lymphocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>Cowpox virus</term>
<term>HIV-1</term>
<term>Orthopoxvirus</term>
<term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Lipides</term>
<term>Mélanome</term>
<term>Peptides</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Melanoma</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Dendritic Cells</term>
<term>T-Lymphocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cellules dendritiques</term>
<term>Lymphocytes T</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Acide glycyrrhizique</term>
<term>Agents antiVIH</term>
<term>Cytosine</term>
<term>Lipides</term>
<term>Peptides</term>
<term>Phosphonates</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Melanoma</term>
</keywords>
<keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr"><term>Agents antiVIH</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Antiretroviral Therapy, Highly Active</term>
<term>Cidofovir</term>
<term>Humans</term>
<term>Major Histocompatibility Complex</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Cellules dendritiques</term>
<term>Complexe majeur d'histocompatibilité</term>
<term>Humains</term>
<term>Lipides</term>
<term>Lymphocytes T</term>
<term>Mélanome</term>
<term>Orthopoxvirus</term>
<term>Peptides</term>
<term>Thérapie antirétrovirale hautement active</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term>
<term>Virus de la variole bovine</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Lipopeptide lipid moieties induce dendritic cell (DC) internalization and epitopes are recognized by MHC, the major histocompatibility complex. HIV-1 (human immunodeficiency virus type 1) lipopeptide vaccine candidate elicits immune responses, and sustains HIV control after highly active antiretroviral therapy (HAART). Mp- and Dp-MART (anti-melanoma lipopeptides) induce strong CTL (cytolytic T lymphocyte) response. New BGTC, BGDA, TGKC lipoplexes mediate gene delivery, e.g., into mouse pancreatic tumor nodules. Triterpene glycyrrhizic acid (GL) inhibits SARS-CoV (severe acute respiratory syndrome associated coronavirus) replication. Compared to CDV (cidofovir), CDV ether lipid esters have enhanced activity against vaccinia (VV) and cowpox (CV) viruses in vitro. Oral treatment of VV and CV infected mice with CDV ether lipid esters, as effective as i.p. CDV, may be useful against orthopoxvirus infections in humans.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
</settlement>
</list>
<tree><country name="France"><region name="Île-de-France"><name sortKey="Raulin, J" sort="Raulin, J" uniqKey="Raulin J" first="J" last="Raulin">J. Raulin</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/France/Analysis

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000336 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000336 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    France
   |étape=   Analysis
   |type=    RBID
   |clé=     pubmed:15892690
   |texte=   Development in lipid drugs.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/France/Analysis/RBID.i   -Sk "pubmed:15892690" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/France/Analysis/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

Serveur d'exploration SRAS

Development in lipid drugs.

Development in lipid drugs.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.